IL6 and COVID-19: As mentioned above, due to the association between the plasma levels of IL-6 and the fatal outcomes of COVID-19, the anti-IL-6 receptor monoclonal antibody tocilizumab was introduced for treatment of the disease, showing reduced mortality, an increased chance of successful hospital discharge, and a reduced risk of invasive mechanical ventilation (104).